New drugs in gynecologic oncology

Curr Opin Oncol. 1996 Sep;8(5):408-14. doi: 10.1097/00001622-199609000-00013.


New agents with activity in recurrent epithelial ovarian cancer include the taxoids (paclitaxel and docetaxel), camptothecins (topotecan and irinotecan), gemcitabine, and oxaliplatin. In front-line therapy, the Gynecologic Oncology Group has shown that paclitaxel prolongs survival. In recurrent squamous carcinoma of the cervix, irinotecan has an objective response rate of 15%-24%. Both paclitaxel and docetaxel also show modest activity. Of these new agents, only paclitaxel has been evaluated in carcinoma of the endometrium, reporting a response rate of 35%.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Camptothecin / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy
  • Clinical Trials as Topic
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Endometrial Neoplasms / drug therapy
  • Female
  • Gemcitabine
  • Genital Neoplasms, Female / drug therapy*
  • Humans
  • Ovarian Neoplasms / drug therapy
  • Platinum Compounds / therapeutic use
  • Uterine Cervical Neoplasms / drug therapy


  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Platinum Compounds
  • Deoxycytidine
  • Camptothecin
  • Gemcitabine